Feb. 13, 2017
Eli Lilly and Company and Incyte Corporation have announced that the European Commission has granted marketing authorisation for Olumiant® (baricitinib) 4 mg and 2 mg film-coated tablets in Europe for treating moderate-to-severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to, one or more disease-modifying antirheumatic drugs (DMARDs).
Anthony Ware, M.D., senior vice president for product development and interim president, Lilly Bio-Medicines, said: “Despite clinical advances in treatment, many people with RA continue to struggle with the debilitating effects of this disease, which can lead to long-term joint damage and disability. We believe that as a next-generation therapy in the EU, Olumiant will advance RA treatment by helping patients with moderate-to-severe disease feel better quickly.”
“The European Commission’s approval of baricitinib is an exciting milestone for the RA community in the EU. We’re confident that baricitinib will help to meet the needs of healthcare providers and their patients as they work toward achieving long-term treatment goals,” said Steven Stein, M.D., chief medical officer, Incyte Corporation.
Due to the approval of Olumiant by the European Commission, Incyte becomes eligible to receive a milestone payment of $65 million from Lilly, which it expects to record in full in the first quarter of 2017.